Escalier Biosciences, Inc.
http://www.escalierbio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Escalier Biosciences, Inc.
Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A
China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.
HRS 2011: What's Hot, What's Not, in AF Ablation
Presenters at a day-long AF Symposium held just prior to this year's Heart Rhythm Society meeting lamented the disappointing long-term results with AF ablation and spoke about upcoming technological advances in catheters and adjunctive tools that may improve the procedure's efficacy and durability.
Top Device Stories of 2010: A Look Back and a Glance Forward
This article was adapted from "Top Device Stories of 2010: Waiting for the Other Shoes to Fall," in the January 2011 issue of IN VIVO.
Top Device Stories Of 2010: Waiting For The Other Shoes To Fall
For much of the device industry, 2010 felt like a transition year, breeding uncertainty in a number of important areas, including the economy, health care reform, and impending changes to the 510(k) process. A review of the year just ended turns up these stories: Device M&A on the Rebound; Is A First-Mover Advantage Emerging In Medtech? Boston Scientific Is Back In The Game; Early-Stage Deals In Decline; The Future Of Medtech: Where Private Investment Dollars Are Flowing; Transcatheter Valves Take Center Stage; Spine's Downturn; Diabetes Assumptions Begin To Shift; A Landmark Year In Ophthalmology; Health Reform In 2010: A Beginning, Not An End; Changes At FDA: 510(k) Reform Takes Shape, and finally, Is Physician Choice In Product Selection In Danger?
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice